<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44931">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02521376</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-339-1631</org_study_id>
    <secondary_id>2016-003266-98</secondary_id>
    <nct_id>NCT02521376</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function</brief_title>
  <official_title>A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib in Subjects With Normal and Impaired Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the pharmacokinetics of Entospletinib
      (ENTO) and/or its metabolites (if applicable) in participants with impaired hepatic function
      (stratified by smoking status, as appropriate) relative to matched, healthy controls.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: AUC</measure>
    <time_frame>Day 1; Day 5</time_frame>
    <description>AUC is defined as the concentration of drug over time (area under the plasma concentration versus time curve)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: Cmax</measure>
    <time_frame>Day 1; Day 5</time_frame>
    <description>Cmax is defined as maximum observed concentration of drug in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Experiencing Adverse Events</measure>
    <time_frame>Up to Day 9 plus 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Experiencing Laboratory Abnormalities</measure>
    <time_frame>Up to Day 9 plus 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Oncology</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (Moderate Hepatic Impairment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entospletinib administered on Days 1-5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (Severe Hepatic Impairment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entospletinib administered on Days 1-5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (Mild Hepatic Impairment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entospletinib administered on Days 1-5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entospletinib</intervention_name>
    <description>Entospletinib 100 mg tablet administered orally twice daily</description>
    <arm_group_label>Cohort 1 (Moderate Hepatic Impairment)</arm_group_label>
    <arm_group_label>Cohort 2 (Severe Hepatic Impairment)</arm_group_label>
    <arm_group_label>Cohort 3 (Mild Hepatic Impairment)</arm_group_label>
    <other_name>GS-9973</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Calculated body mass index from 18 to 40 kg/m^2

          -  Not pregnant

          -  Normal electrocardiogram

          -  Participants with impaired liver function must be sufficiently healthy based upon
             medical history and physical examination, vital signs, and screening laboratory
             evaluations.

        Exclusion Criteria:

          -  Participation in another clinical study (current or within last 30 days)

          -  HIV, hepatitis B virus, or active hepatitis C virus infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>339-1631Study@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, Inc. (CPMI)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>APEX GmBH</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust Ltd</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 10, 2017</lastchanged_date>
  <firstreceived_date>August 10, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
